|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Peripheral neuropathy: a persisting challenge in paclitaxel-based re- gimes 显示文摘 | MIELKE S SPARREBOOM A MROSS K | 2006 | Eur J Cancer2006，42，1： | 1 |
| 2 | A phase I dose-escalation study of regorafenib ( BAY 73-4506 ) , an inhibitor of oneogenie, angiogenic, and stromal kinases, in patients with advanced solid tumors 显示文摘 | Mross K Frost A Steinbild S | 2012 | Clin Cancer Res2012，18，9： | 1 |
| 3 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours 显示文摘 | Mross K Drevs J Muller M | 2005 | Eur J Cancer2005，41，9： | 1 |
| 4 | Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans 显示文摘 | Mross K Maessen P van der Vijgh W J | 1988 | J Clin Oncol1988，6，3： | 1 |
| 5 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor,in patients with liver metasta- ses from solid tumors显示文摘 | Mross K Drevs J Muller M Medinger M Marine D Hennig J | 2005 | Eur J Cancer2005，41，9： | 1 |
| 6 | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia 显示文摘 | Sissung TM Mross K Steinberg SM | 2006 | Eur J Cancer2006，42，： | 1 |
| 7 | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia显示文摘 | Sissung TM Mross K Steinberg SM | 2006 | Eur J Cancer2006，42，17： | 1 |
| 8 | Topotecan-A novel topoisomerase I inhibitor: pharmacology and clinical experience显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
| 9 | Phase I study of the angiogenesis inhibitor BIBF1 120 in patients with advanced solid tumors显示文摘 | Mross K Stefanic M Gmehling D | 2010 | Clin Cancer Res2010，16，1： | 1 |
| 10 | PAC fixed dose:pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing显示文摘 | Mross K Hollender N Frost A | 2006 | Onkologie2006，29，10： | 1 |
| 11 | Topotecan-A novel topolsomerase linhibitor:pharmacology and clinical experience显示文摘 | Kollmannsberger C Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
| 12 | Topotecana novel topoisomerase Ⅰ inhibitor:pharmacology and clinical experience 显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，： | 1 |
| 13 | A phase I doseescalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors 显示文摘 | Mross K Frost A Steinbild S | 2012 | Clin Cancer Res2012，18，9： | 1 |
| 14 | A phase I dose-escalation study of BI 811283,an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors 显示文摘 | MROSS K B SCHEULEN M E FROST A | 2010 | J Clin Oncol2010，28，15： | 1 |
| 15 | Topotecan-A novel topoisomerase I inhibitor:pharmacology and clinical experience显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
| 16 | Topotecan-a novel topoisomerase I inhibitor:pharmacology and clinical experience显示文摘 | Kollmannsberger C Mross K Jakob A | 1999 | Oncology1999，561，： | 1 |
| 17 | A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15, every four weeks in patients with advanced solid tumors 显示文摘 | SCHEULEN M E MROSS K B RICHLY H | 2010 | J Clin Oncol2010，28，15： | 1 |
| 18 | Topotecana novel topoisomerase I inhibitor:pharmacology and clinical experience显示文摘 | Kollmannsberger C Mross K Jakob A | 1999 | Oncology1999，56，： | 1 |
| 19 | Phase I clinical and pharmacokinetic study of PrrK/ZK,a muhiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours 显示文摘 | Mross K Drevs J Muller M | 2005 | Eor J Cancer2005，41，9： | 1 |
| 20 | A phase I dose - escalation study of regorafenib ( BAY 73 -4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors 显示文摘 | MROSS K FROST A STEINBILD S | 2012 | Clin Cancer Res2012，18，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员